Clinical Trial Update: A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 safety and tolerability study of HJB647 in patients with heart failure with reduced ejection fraction, which is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• HJB647

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 1 | Status: RECRUITING